phospholipase C delta 1Genealiases: NDNC3 · PLC-III
Q-omics provides the consensus-scored PLCD1 profile across patient tissues and cancer cell-line models. PLCD1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, PLCD1 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, PLCD1 protein abundance shows 28,968 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight UVM, COAD, and LUAD as cancer lineages where PLCD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PLCD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PLCD1 survival associations across molecular data types. PLCD1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PLCD1 RNA expression–survival associations across cancer types. High PLCD1 expression shows favorable associations in UVM, KIRP, KIRC, MESO, CESC and BRCA. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for PLCD1 RNA expression.
This table summarizes PLCD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PLCD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PLCD1 shows lower tumor expression in COAD, KIRC, KICH, LUAD and READ and higher tumor expression in THCA. The COAD box plot shows higher PLCD1 RNA expression in normal versus tumor tissue (log2 FC = −2.278, t-test p < 0.001).
This table shows molecular features associated with PLCD1 in patient tissues and cancer cell lines. In patient samples, PLCD1 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, PLCD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
